On Tuesday, Ohio voters will cast ballots in primary elections to select each party’s nominee for governor.
The candidates have been talking about marijuana reform on the campaign trail, and we’ve compiled a list detailing each major contender’s stance on the issue.
Richard Cordray, former director of the Consumer Financial Protection Bureau
Seen by some political observers as the favorite to win the Democratic primary nomination, Cordray has been evasive about his stance on marijuana reform since announcing his candidacy in December 2017. The establishment Democrat, endorsed by Massachusetts Sen. Elizabeth Warren (D), has only gone so far as to say that he would respect Ohio voters’ decision if they opted to legalize marijuana and vowed to improve Ohio’s existing medical marijuana program—but he’s declined to clarify his personal views on reform.
“As Governor, Rich Cordray will fix the botched implementation of Ohio’s medical marijuana program to ensure that patients have access to the medicine they need in a safe and affordable manner,” spokesperson Mike Gwin told Marijuana Moment. “He also thinks that the last marijuana ballot referendum failed partly because it was a flawed proposal. He supports voters’ right to propose a new referendum and will follow the will of the voters if it comes to a vote.”
Former Ohio Supreme Court justice Bill O’Neill, one of Cordray’s challengers, offered to drop out of the race if the candidate adopted his pro-legalization stance. But asked to comment on the challenger’s proposal in December, Cordray said simply, “I don’t have anything much to say about that today,” The Statehouse News Bureau reported.
Dennis Kucinich, former U.S. House representative
Though Cordray is considered the “conventional” favorite to win the Democratic primary nomination, Kucinich is his closest competition and still stands a “good chance” of winning, Cleveland.com reported. And when it comes to the issue of marijuana legalization, the former U.S. representative stands in stark contrast to his opponent. Kucinich has campaigned on a consistently pro-legalization agenda—and co-sponsored several bills during his tenure in Congress, ranging from the legalization of agricultural hemp to ending the federal prohibition of marijuana.
I’ve said a lot on these issues. Here are some snippets from my announcement speech. I support #IndustrialHemp and #Marijuana legalization. Check out our extensive platform @ https://t.co/duVmZCJfJL and my record in Congress on these issues. #PowerToWeThePeople #Kucinich4Ohio pic.twitter.com/jYHt79EPQ1
— Dennis Kucinich (@Dennis_Kucinich) February 20, 2018
In March, Kucinich announced that part of his agenda if elected governor would involve working to legalize recreational marijuana and hemp in the state, and allowing medical marijuana patients to grow cannabis for personal use. He’s also argued that expanding access to cannabis would provide pain patients with an alternative to addictive and dangerous painkillers in a state that has been hit hard by the opioid epidemic.
Bill O’Neill, former Ohio Supreme Court justice
Political analysts don’t consider O’Neill a particularly strong contender in the Democratic gubernatorial primary—due in no small part to his brazen social media posts about his past sexual escapades in the wake of misconduct allegations against former Minnesota Sen. Al Franken (D). His viability as a candidate has also been questioned given his lack of name recognition and campaign funding. That said, O’Neill has unequivocally championed marijuana reform throughout his candidacy.
His campaign website reads clearly: “Marijuana should be legal in Ohio. It has many non-addictive medicinal qualities; reduces the dependence on opioids and alcohol; and is a proven job, tax and income producer.”
Early into his run for governor, O’Neill said that he would bow out of the race if Cordray threw his hat into the ring, but he’s since said that he “wants Cordray to agree with him on marijuana legalization and reopening shuttered state mental hospitals to treat opioid addicts,” before he’s willing to exit the race. Cordray declined to comment on O’Neill’s proposal.
.@RichCordrayOH says he doesn't have anything to say about @BillForOhio calling on him to make legalization of marijuana part of his platform. O'Neill said he'd drop out if Cordray does.
— Ben Garbarek (@BenWSYX6) December 5, 2017
Joseph Schiavoni, Ohio senator
The former boxer and current state senator’s candidacy has been met with skepticism— but on at least one issue, he stands out in his adamant support for medical and recreational marijuana legalization in Ohio. He’s co-sponsored legislation in the state to provide access to cannabis for medical marijuana patients and, according to his campaign site, feels that recreational legalization “would provide needed funding to our state and allow police to focus resources on more pressing matters,” adding that any such laws would have to be passed “properly.”
“For example, we need to make sure the money this new industry generates is directed at something specific, such as Ohio’s education system. It should not just go to the state and disappear,” a statement on his campaign site reads.
Two other Democratic candidates, Paul Ray and Larry Ealy, qualified for the November ballot, but their stances on marijuana reform—among many other issues—are unknown. Ray, a candidate who is seemingly without a digital footprint and Ealy, a former exotic dancer who ran for Ohio governor in 2014, are not considered strong candidates by most conventional measures.
Mike DeWine, Ohio attorney general
DeWine is the favorite to win Ohio’s Republican gubernatorial nomination—and he’s resistant to marijuana reform, to say the least. Just days ago, on April 20, the state’s attorney general rejected a petition that sought to fully legalize marijuana in Ohio, Cincinnati.com reported, though he explained that the move had to do with the measure’s language, not its subject matter. The attorney general also visited Colorado in October 2015 to assess how the state’s recreational marijuana system was playing out, but after witnessing the popularity of edibles in the state, he said he was “alarmed.”
Mary Taylor, Ohio lieutenant governor
Though there are few public details about Taylor’s personal stance on medical marijuana legalization, we know at least two things: 1) she’s on the record opposing recreational legalization, and 2) she was vocal in a push to freeze approvals on marijuana grower applications in the state in December 2017 after it was discovered that a convicted drug dealer had been hired as a consultant to grade applicants.
Kansas Medical Marijuana Hearings Cancelled After Senate GOP Leader Reroutes House-Passed Bill
A House-passed bill to legalize medical marijuana in Kansas seems to be in jeopardy, with GOP Senate leadership moving the legislation out of a committee and into a different panel where it may sit in legislative limbo, resulting in the cancellation of hearings that were scheduled to be held this week.
Advocates are concerned about the decision by Senate President Ty Masterson (R), who withdrew the cannabis reform legislation from the Senate Federal and State Affairs Committee days before hearings were to be held on Tuesday and Wednesday. It was then re-referred to the Senate Interstate Cooperation Committee, which Masterson chairs and where the bill’s fate is unclear.
This doesn’t necessarily mean that medical marijuana legalization is off the table for Kansas in 2022, but it does seem to signal that the reform might need to be enacted through another vehicle, either in the legislature or at the ballot, as top Democratic lawmakers in the state are pursuing.
“We certainly hope that this action is just making sure that this bill meets any concerns that Senate leadership may have concerning this historic legislation,” Kevin Caldwell, a legislative manager at Marijuana Policy Project (MPP), told Marijuana Moment. “This bill had widespread bipartisan support in the House last session. We hope Senate President Masterson quickly holds a committee hearing and advances this legislation.”
When the proposal was being advanced in the House last year during the first half of the two-year session, members amended an unrelated bill that previously cleared the Senate to make it the chamber’s vehicle for the policy change. Because of that, it was ruled “materially changed” last May and sent to the Senate for committee consideration.
Now there’s a question of whether lawmakers will be motivated to introduce another separate bill and try to move it through both chambers, requiring another House vote. The Senate president seemed to temper expectations in recent remarks, telling The Kansas City Star that “not a single member” of his caucus has expressed that the issue “was important to them.”
That’s not how Kansas Democrats feel, however. House Minority Leader Tom Sawyer (D) and Assistant Minority Leader Jason Probst (D) said this month that they will be introducing proposals to let voters decide on legalizing medical and adult-use marijuana in the state. At the time, Sawyer said he was “hopeful” that the legislature might separately advance the House-passed legalization measure.
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
“The people of Kansas deserve to know if senators support the overwhelming majority of people who want to alleviate patients’ suffering with a medical cannabis program,” MPP’s Caldwell said. “Now is the time to show compassion to their fellow citizens and vote this bill out of committee.”
“Kansas is one of fourteen states left without a medical cannabis program,” he said. “We have faith that the Kansas Senate will pass this legislation this session and this is just another step in that process.”
Michael Pirner, Masterson’s communications director, told the Star that “medical marijuana legislation is not a priority of Senate leadership,” but did signal the issue may still be considered before the year is over.
“The subject matter has clearly matured and we expect it to be considered at some level this session,” he said. “There are many more pressing topics on the Senate agenda.”
The bill as drafted contains several significant restrictions, including a ban on smokeable cannabis. Members of the Senate Federal and State Affairs Committee did get a briefing on the issue at a meeting last week ahead of the expected, now-cancelled formal hearings before the panel.
Meanwhile, the constitutional amendment that the Democratic leaders are proposing would provide for a more comprehensive program that lawmakers would need to implement.
Gov. Laura Kelly (D), for her part, wants to see medical cannabis legalization enacted, and she said at a briefing with reporters on Friday that she “absolutely” thinks the bill could pass if “everything else doesn’t take up all the oxygen.”
She previously pushed a separate proposal that would legalize medical cannabis and use the resulting revenue to support Medicaid expansion, with Rep. Brandon Woodard (D) filing the measure on the governor’s behalf.
Kelly has she said she wants voters to put pressure on their representatives to get the reform passed.
The governor also said in 2020 that while she wouldn’t personally advocate for adult-use legalization, she wouldn’t rule out signing the reform into law if a reform bill arrived on her desk.
Photo courtesy of Philip Steffan.
Marijuana Banking Bill Sponsor Says He’s ‘Gonna Get That Darn Thing Passed’ Before Leaving Office
Rep. Ed Perlmutter (D-CO) is retiring from Congress at the end of this session, but he says that he’s going to work to pass his marijuana banking bill before his time on Capitol Hill comes to an end.
The congressman spoke to Colorado Public Radio last week about his decision not to run for reelection this November and his disappointment that, while the House has approved the Secure and Fair Enforcement (SAFE) Banking Act five times now in some form, the Senate has failed to advance it under both Republican and Democratic leadership.
“That one still has me pretty irritated,” Perlmutter said, referring to the fact that Senate Majority Leader Chuck Schumer (D-NY) has effectively blocked his bipartisan legislation. When there was a GOP Senate majority, he was told the bill was “too big and too broad.” Then with a Democratic majority, he’s told that it’s “too narrow and too limited.”
Schumer and his colleagues who are working on a federal legalization bill have repeatedly said that they do not want to see the SAFE Banking Act pass before comprehensive reform is enacted that addresses equity issues. Supporters of the banking bill argue that the incremental policy change is necessary for promote public safety and, importantly, it stands a much stronger chance of getting to the president’s desk with bipartisan support.
Nonetheless, Perlmutter said he plans to spend his remaining months in office pushing to get the job done.
“I have not given up on that one,” he said. “I’m gonna get that darn thing passed this year while I still serve out my term.”
Listen to Perlmutter discuss the marijuana banking legislation, starting around 10:24 into the audio below:
Asked whether he thinks President Joe Biden would be inclined to sign the measure if it did get to his desk, the congressman said “absolutely.”
“Treasury Secretary [Janet] Yellen is somebody who has been talking to me about this for years,” he said. “I feel very good that it would pass. We’re at 47 states that have some level of marijuana use, all the territories and District of Columbia, and they need to have legitimate banking services.”
“It’s just a no brainer in my opinion,” he said. “And yeah, I’m a little bit irritated, but we’re gonna keep working on it and get it passed this year.”
The last attempt that Perlmutter made to enact the reform was by adding its language to a must-pass defense bill, but it was ultimately sidelined following bicameral negotiations and did not make it into the final version. The congressman told Marijuana Moment last month that he sees other potential vehicles to advance the bill and has spoken with House Speaker Nancy Pelosi (D-CA) about it.
Even some Republicans are scratching their heads about how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue last month.
Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads
A top federal drug official says the “train has left the station” on psychedelics.
National Institute on Drug Abuse (NIDA) Director Nora Volkow said people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn to the potential therapeutic benefits—and so researchers and regulators will need to keep up.
The comments came at a psychedelics workshop Volkow’s agency cohosted with the National Institute of Mental Health (NIMH) last week.
The NIDA official said that, to an extent, it’s been overwhelming to address new drug trends in the psychedelics space. But at the same time, she sees “an incredible opportunity to also modify the way that we are doing things.”
“What is it that the [National Institutes of Health] can do to help accelerate research in this field so that we can truly understand what are the potentials, and ultimately the application, of interventions that are bought based on psychedelic drugs?” Volkow said.
The director separately told Marijuana Moment on Friday in an emailed statement that part of the challenge for the agency and researchers is the fact that psychedelics are strictly prohibited as Schedule I drugs under the federal Controlled Substances Act.
“Researchers must obtain a Schedule I registration which, unlike obtaining registrations for Schedule II substances (which include fentanyl, methamphetamine, and cocaine), is administratively challenging and time consuming,” she said. “This process may deter some scientists from conducting research on Schedule I drugs.”
“In response to concerns from researchers, NIDA is involved in interagency discussions to facilitate research on Schedule I substances,” Volkow said, adding that the agency is “pleased” the Drug Enforcement Administration recently announced plans to significantly increase the quota of certain psychedelic drugs to be produced for use in research.
“It will also be important to streamline the process of obtaining Schedule I registrations to further the science on these substances, including examining their therapeutic potential,” she said.
At Thursday’s event, the official talked about how recent, federally funded surveys showed that fewer college-aged adults are drinking alcohol and are instead opting for psychedelics and marijuana. She discussed the findings in an earlier interview with Marijuana Moment as well.
Don't miss out on the @NIDAnews, @NIAAAnews, & @NIMHgov-sponsored virtual Workshop on Psychedelics as Therapeutics: Gaps, Challenges, and Opportunities, Jan. 12‒13, 2022. Learn more and register: https://t.co/S1zttkoYXq pic.twitter.com/C2Qrk6FN9a
— NIDAnews (@NIDAnews) January 10, 2022
“Let’s learn from history,” she said. “Let’s see what we have learned from the marijuana experience.”
While studies have found that marijuana use among young people has generally remained stable or decreased amid the legalization movement, there has been an increase in cannabis consumption among adults, she said. And “this is likely to happen [with psychedelics] as more and more attention is placed on these psychedelic drugs.”
“I think, to a certain extent, with all the attention that the psychedelic drugs have attracted, the train has left the station and that people are going to start to use it,” Volkow said. “People are going to start to use it whether [the Food and Drug Administration] approves or not.
There are numerous states and localities where psychedelics reform is being explored and pursued both legislatively and through ballot initiative processes.
On Wednesday—during the first part of the two-day federal event that saw nearly 4,000 registrants across 21 time zones—NIMH Director Joshua Gordon stressed that his agency has “been supporting research on psychedelics for some time.”
Tune in today and tomorrow for the @NIH workshop on Psychedelics as Therapeutics, which will examine findings on psychoplastogens for treating depression, post-traumatic stress, and substance and alcohol use disorders. https://t.co/Qzxte5xJt9
— Joshua A. Gordon (@NIMHDirector) January 12, 2022
“We can think of NIMH’s interests in studying psychedelics both in terms of proving that they work and also in terms of demonstrating the mechanism by which they work,” he said. “NIMH has a range of different funding opportunity announcements and other expressions that are priorities aimed at a mechanistic focus and mechanistic approach to drug development.”
Meanwhile, Volkow also made connections between psychedelics and the federal response to the coronavirus pandemic. She said, for example, that survey data showing increased use of psychedelics “may be a way that people are using to try to escape” the situation.
But she also drew a metaphor, saying that just as how the pandemic “forced” federal health officials to accelerate the development and approval of COVID-19 vaccines because of the “urgency of the situation,” one could argue that “actually there is an urgency to bring treatments [such as emerging psychedelic medicines] for people that are suffering from severe mental illness which can be devastating.”
But as Volkow has pointed out, the Schedule I classification of these substances under federal law inhibits such research and development.
The official has also repeatedly highlighted and criticized the racial disparities in drug criminalization enforcement overall.